Instruction for use: Interferon beta

Trade name of the drug – Interferon beta-1a human recombinant

The Latin name of the substance Interferon beta

Interferonum beta (genus. Interferoni beta)

Pharmacological groups:

Interferons

Antiviral drugs (excluding HIV)

Nosological classification (ICD-10)

A60 Anogenital herpetic viral infection [herpes simplex]: Herpes simplex genitalis; Banal recurrent genital herpes; Secondary genital herpes; Genital herpesvirus infection; Genital herpetic infections; Genital herpes; Herpes genitalia; Genital herpes; Herpes simplex organs; Herpetic lesions of the mucocutaneous urinary organs; Herpetic lesions of the genitals; Primary genital herpes; Primary herpes simplex; Simple herpes extragenital and genital localization; Recurrent genital herpes; Recurrent herpes of genital organs; Herpes of the lips and genitals

A63.0 Anogenital (venereal) warts: Anogenital warts; Venereal warts; Condylomata genital; Condyloma pointed; Externally pointed genital warts; Externally pointed condyloma; Pointed Condyloma; Flat condyloma

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B02 Shingles [herpes zoster]: Herpes zoster; Herpes zoster; Shingles Herpes; Localized shingles; Infection caused by the herpes zoster virus; Shingles

B07 Viral Warts: Warts; Human Wart Virus; Vulgar warts; Flat wart; Flat and vulgar wart in children; Plantar wart; Common wart; Common plantar wart; Skin Papillomas

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

C50 Malignant neoplasm of breast: Nipple cancer and areola of mammary gland; Breast carcinoma; The hormone-dependent form of recurrent breast cancer in women in menopause; Hormone-dependent breast cancer; Disseminated breast carcinoma; Disseminated breast cancer; Malignant breast cancer; Malignant neoplasm of breast; Contralateral breast cancer; Locally advanced or metastatic breast cancer; Locally-distributed breast cancer; Locally-recurring breast cancer; Metastatic breast carcinoma; Metastasis of breast tumors; Metastatic breast carcinoma; Inoperable breast carcinoma; Incompatible breast cancer; Breast cancer in women with metastases; Breast cancer in men with metastases; Breast Cancer; Breast cancer in men; Mammary cancer; Breast cancer with distant metastases; Breast cancer in postmenopausal women; Breast cancer hormone-dependent; Breast cancer with local metastases; Breast cancer with metastases; Breast cancer with regional metastases; Breast cancer with metastases; Common hormone-dependent forms of breast cancer; Common Breast Cancer; Recurrent Breast Cancer; Recurrence of breast tumors; Breast cancer; Estrogen-dependent breast cancer; Estrogen-Dependent Breast Cancer; Disseminated breast cancer with overexpression of HER2; Tumors of the mammary glands

C53 Malignant neoplasm of cervix: Intraepithelial neoplasm of cervix uteri; Cervical carcinoma; Cervical cancer

C54 Malignant neoplasm of uterus: Uterine cancer; Cancer of the body of the uterus; Sarcoma of the uterus

C91.4 Hairy-cell leucosis

K73 Chronic hepatitis, not elsewhere classified: Inflammatory liver disease; Hepatitis autoimmune; Hepatitis chronic; Infection of the liver; Chronic hepatitis with signs of cholestasis; Chronic reactive hepatitis; Chronic persistent hepatitis; Chronic infectious hepatitis; Chronic active hepatitis; Chronic inflammatory liver disease; Autoimmune Hepatitis; Chronic hepatitis is aggressive

Characteristics of the substance Interferon beta

Sterile lyophilized powder.

Pharmacology

Pharmacological action - antiviral, immunomodulating, antiproliferative.

It binds to specific receptors on the cell surface and causes gene expression and the synthesis of certain products, such as 2 ', 5'-oligoadenylate synthetase, neopterin, beta2-microglobulin. With the / m introduction of Cmax is achieved after 3-15 hours, and then decreases at a constant rate, T1 / 2 - 10 hours. The biological response is manifested by the administration of 15-75 μg. The levels of neopterin and beta2-microglobulin increase after 12 hours and remain so for 4 days. The maximum response occurs after 48 hours.

Application of substance Interferon beta

Genital herpes, papillomas caused by the human wart virus, flat and pointed condylomas, simple and herpes zoster, chronic hepatitis B in adults with the presence of viral replication markers, viral hepatitis C in the presence of replication markers and without signs of hepatocellular insufficiency, intraepithelial tumor of the cervix , Neoplastic pleural effusion, hairy cell leukemia, induction of steroid receptors in breast carcinoma or endometrial carcinoma followed by hormone therapy .

Contraindications

Hypersensitivity, severe heart disease, hepatic-cell insufficiency, chronic hepatitis against the background of previous or ongoing treatment with cytostatics (except for a short course of steroids), autoimmune hepatitis, renal dysfunction, CNS diseases (including epilepsy), previous diseases Thyroid gland in the absence of appropriate therapy, pregnancy.

Restrictions

Depressive states (and suicidal ideation), angina, rhythm disturbances, congestive heart failure.

Side effects of the substance Interferon beta

Leukopenia, thrombocytopenia, anemia, autoimmune hemolysis, anorexia, diarrhea, increased transaminase levels, hypotension, tachycardia, dyspnea, dizziness, sleep disorders, bone and joint pains, fever, weakness, myalgia, headaches, nausea, vomiting; With prolonged use - hair loss.

Routes of administration

Parenteral.

Precautions for the substance Interferon beta

Treatment is carried out under the strict supervision of a physician. Be wary appoint patients with myocardial damage. It should be borne in mind the likelihood of developing thyroid dysfunction. A careful control of the level of leukocytes, platelets and electrolyte blood composition is necessary. With a significant increase in temperature, intoxication, blood pressure fluctuations for a long time, you should reduce the dose or cancel the drug.